<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NALIDIXIC ACID</span><br/>(nal-i-dix'ik)<br/><span class="topboxtradename">NegGram<br/></span><b>Classifications:</b> <span class="classification">urinary tract antiinfective</span>; <span class="classification">antibiotic, quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>B (second and third trimester)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic quinolone. Intracellular action (by unknown mechanism) inhibits microbial DNA replication and RNA synthesis.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Marked bactericidal activity against most gram-negative urinary tract pathogens with the exception of strains of <i>Pseudomonas</i>. Also effective against some strains of <i>Shigella</i> and <i>Salmonella</i>. Gram-positive bacteria are relatively resistant to drug action.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Urinary tract infections caused by susceptible gram-negative organisms including most <i>Proteus</i> strains, <i>Klebsiella, Enterobacter,</i> and <i>Escherichia coli.</i>
</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>GI tract infections caused by susceptible strains of <i>Shigella sonnei;</i> prophylaxis of bacteriuria and in bladder irrigation for low-grade cystitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of convulsive disorders; first trimester of pregnancy; infants 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Prepubertal child; second and third trimesters of pregnancy (category B); kidney or liver disease; epilepsy; cerebral arteriosclerosis;
         respiratory insufficiency; patients and breast-feeding infants with G6PD deficiency.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Acute therapy: 1 g q.i.d. Chronic therapy: 500 mg q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;3 mo,</i> Acute therapy: 55 mg/kg/d in 4 divided doses; Chronic therapy: 33 mg/kg/d in 4 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or milk if drug causes GI distress. Otherwise, give on an empty stomach 1 h before or 2 h after meals.</li>
<li>Store at 15°30° C (59°86° F) in tight container and avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Angioedema, fever, chills, arthralgia, hypersensitivity pneumonitis, <span class="speceff-life">anaphylaxis</span> (rare). <span class="typehead">CNS:</span> Drowsiness, headache, malaise, dizziness, vertigo, syncope, weakness, myalgia, peripheral neuritis, confusion, excitement,
      mental depression, seizures, insomnia. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">nausea, vomiting,</span> diarrhea, cholestasis, transient increase in AST. <span class="typehead">Hematologic:</span> Eosinophilia, hemolytic anemia (especially in G6PD deficiency). <span class="typehead">Skin:</span> Photosensitivity, pruritus, urticaria, rash. <span class="typehead">Other:</span> Cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-positive urine tests for <span class="alt">glucose</span> with <span class="alt">cupric sulfate reagent</span> (e.g., <span class="alt">Benedict's</span> or <span class="alt">Clinitest</span>) but not with <span class="alt">glucose oxidase methods</span> (e.g., <span class="alt">Clinistix,</span>
<span class="alt">TesTape</span>). May cause elevation of <span class="alt">urinary 17-ketosteroids</span>
<span class="alt">(Zimmerman method)</span> and <span class="alt">urine vanillylmandelic acid</span>
<span class="alt">(VMA).</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification"> antacids</span>, <b>sucralfate,</b>
<b>calcium,</b>
<b>magnesium,</b>
<b>didanosine,</b>
<span class="classification">multivitamins</span> (containing <b>iron</b> or <b>zinc</b>) may decrease absorption of nalidixic acid; may increase hypoprothrombinemic effects of <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> Urine: 34 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Partially metabolized in liver; some metabolism in kidneys. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 1.12.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Perform C&amp;S tests prior to initiation of treatment and periodically thereafter. Obtain blood counts and kidney
            or liver function tests if therapy is continued longer than 2 wk.
         </li>
<li>Watch for CNS reactions, which tend to occur 30 min after initiation of treatment or after second or third dose. Infants,
            children, and older adults are especially susceptible. Report immediately the onset of marked irritability, vomiting, bulging
            of anterior fontanelle, headache, excitement or drowsiness, papilledema, vertigo.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use drug exactly as prescribed and do not change dosage. Omitted doses, especially in early days of therapy, may promote development
            of bacterial resistance. Take full amount of medication.
         </li>
<li>Contact physician immediately for unexplained behavior changes or severe headaches.</li>
<li>Maintain adequate hydration (20003000 mL/d if tolerated) during treatment period. Consult physician if you notice a
            change in your urination pattern.
         </li>
<li>Avoid exposure to direct sunlight or ultraviolet light while receiving drug. Contact physician if photosensitivity occurs.
            You may be photosensitive up to 3 mo after termination of drug.
         </li>
<li>Contact your physician if you notice visual disturbances during first few days of therapy. Symptoms usually disappear promptly
            with reduction of dosage or discontinuation of therapy.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>